• Baird Medical posted fiscal 2025 net loss of US$27.5 million, swinging from net income of US$12.6 million a year earlier.
• Revenue fell 39.2% to US$22.5 million.
• Operating result flipped to operating loss of US$25.6 million from operating income of US$15.3 million.
• Gross margin narrowed 4.4 percentage points to 83.8%.
• Company said it expects sufficient working capital to operate for at least 12 months from issuance of fiscal 2025 financial statements, backed by support commitments from controlling shareholder Betters Medical Investment Holdings Limited and CEO Haimei Wu.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baird Medical Investment Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-048641), on April 24, 2026, and is solely responsible for the information contained therein.